<p>
    Exception Points:
</p>
<p>
    For the following MELD exceptions, start at 22 and then increase by 3 points every 3 months to a max of 40 (or 30 in the case of HCC).&nbsp;
</p>
    <table class="table table-bordered">
        <tbody>
            <tr class="table-secondary">
                <td>
                    Condition&nbsp;
                </td>
                <td>
                    Indication&nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    Metabolic Disorders&nbsp;
                </td>
                <td>
                    Significant portal hypertension&nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    Hepatopulmonary syndrome&nbsp;
                </td>
                <td>
                    PaO2 &lt; 60 mmHg on ABG&nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    Hepatic Hydrothorax&nbsp;
                </td>
                <td>
                    <p>
                        If the following is met:
                    </p>
                    <ol>
                        <li data-list-item-id="e46475136b7ab1253573d0b9939da7df3">
                            &nbsp; &nbsp;1 thoracentesis over 1 L weekly in last 4 weeks
                        </li>
                        <li data-list-item-id="e0d2f074179f7feca5939e6d0c4f334d0">
                            &nbsp; &nbsp;Pleural fluid is transudative by pleural albumin-serum albumin gradient of at least 1.1 and by cell count
                        </li>
                        <li data-list-item-id="e509870350f12d80b97fea4bf65adf387">
                            &nbsp; &nbsp;No evidence of heart failure
                        </li>
                        <li data-list-item-id="efaae2ae6f7be57ea9ace326a508df2c8">
                            &nbsp; &nbsp;Pleural fluid culture negative on 2 separate occasions
                        </li>
                        <li data-list-item-id="e83f66fad00805ae766bda9aa31efef4e">
                            &nbsp; &nbsp;Pleural fluid cytology is benign on 2 separate occasions
                        </li>
                        <li data-list-item-id="e9c4b8d8947388fd72ca6ddb3eaed87a2">
                            &nbsp; &nbsp;Contraindication to TIPS
                        </li>
                        <li data-list-item-id="ef4074b991e40bd93ce20437b2681dbfe">
                            &nbsp; &nbsp;Diuretic refractory&nbsp;
                        </li>
                    </ol>
                </td>
            </tr>
            <tr>
                <td>
                    Pruritus&nbsp;
                </td>
                <td>
                    <p>
                        If the following is met:
                    </p>
                    <ol>
                        <li data-list-item-id="e86dbed6db26381f627a07766fcc90fed">
                            &nbsp; &nbsp;Intractable pruritus secondary to underlying cholestatic liver disease and documented elevation of serum bile acid levels.
                        </li>
                        <li data-list-item-id="e74c543b9047be1df2c8c20c6840fb212">
                            &nbsp; &nbsp;Severely impacted or impaired quality of life. &nbsp;
                        </li>
                        <li data-list-item-id="efa556f80410abdd765ba79eb0adcdaeb">
                            &nbsp; &nbsp;Refractory to medical therapy (Cholestyramine, Rifampicin, Naltrexone and sertraline) and plasmapheresis.&nbsp;
                        </li>
                    </ol>
                </td>
            </tr>
            <tr>
                <td>
                    Portopulmonary Hypertension&nbsp;
                </td>
                <td>
                    <p>
                        If the following is met:
                    </p>
                    <ol>
                        <li data-list-item-id="e2de9c29843c879f21d721efb3f70a14f">
                            &nbsp; &nbsp;Initial MPAP should be &gt;35 mmHg and PVR levels should be &gt; 240 dynes.s.cm.
                        </li>
                        <li data-list-item-id="e26c10f5326304cf3058bbe45adc5be50">
                            &nbsp; &nbsp;MPAP remains below 35 mmHg with treatment confirmed by repeat heart catheterization.&nbsp;
                        </li>
                    </ol>
                </td>
            </tr>
            <tr>
                <td>
                    Hepatic Epithelioid Hemangioendothelioma&nbsp;
                </td>
                <td>
                    <p>
                        If the following is met:
                    </p>
                    <ol>
                        <li data-list-item-id="e4175125b48a7968a7d4b1ea0d44b3b0c">
                            &nbsp; &nbsp;Biopsy proven.
                        </li>
                        <li data-list-item-id="e01826f8d6963eeb6504e3f02a596a8f4">
                            &nbsp; &nbsp;Not surgically resectable &nbsp;
                        </li>
                    </ol>
                </td>
            </tr>
            <tr>
                <td>
                    Hereditary Hemorrhagic Telangiectasia&nbsp;
                </td>
                <td>
                    <p>
                        If the following is met
                    </p>
                    <ol>
                        <li data-list-item-id="e77d19b1160a892567b7627572cff1bb1">
                            &nbsp; &nbsp;Documentation of high output cardiac failure by echocardiography
                        </li>
                        <li data-list-item-id="e7239f10313a7f72bf8f4851227e10438">
                            &nbsp; &nbsp;Imaging supporting intra-hepatic AV malformations or severe diffuse bilobar hepatic necrosis. &nbsp;
                        </li>
                    </ol>
                </td>
            </tr>
            <tr>
                <td>
                    Multiple Hepatic Adenomas&nbsp;
                </td>
                <td>
                    <p>
                        If the following is met:
                    </p>
                    <ol>
                        <li data-list-item-id="e657c0c44735dfa8af0a6d80d8a4c888e">
                            &nbsp; &nbsp;Not amenable to resection. &nbsp;
                        </li>
                        <li data-list-item-id="eb0c1a7c1ab616b2632ce80e35a8dd1b6">
                            &nbsp; &nbsp;Malignant transformation proven by biopsy. &nbsp;
                        </li>
                        <li data-list-item-id="ef234ae4284da0f39c9968479f00d261c">
                            &nbsp; &nbsp;Presence of glycogen storage disease which increases the risk for malignant transformation.&nbsp;
                        </li>
                    </ol>
                </td>
            </tr>
            <tr>
                <td>
                    Neuroendocrine Tumors &nbsp;
                </td>
                <td>
                    <p>
                        If the following is met:
                    </p>
                    <ol>
                        <li data-list-item-id="e8a52d6e2b28f37ad06e6ef4c232900d6">
                            &nbsp; &nbsp;Recipient age &lt;60 years
                        </li>
                        <li data-list-item-id="e41573387f3a499c20e1c25febfbba11c">
                            &nbsp; &nbsp;Resection of primary malignancy and extra-hepatic disease without any evidence of recurrence at least six months prior to MELD exception request. &nbsp;
                        </li>
                        <li data-list-item-id="e1b4bfb7610debe4109b6b01d26a61c43">
                            &nbsp; &nbsp;Neuroendocrine Liver Metastasis limited to the liver, Bi-lobar, not amenable to resection.&nbsp;
                        </li>
                    </ol>
                </td>
            </tr>
            <tr>
                <td>
                    Polycystic Liver Disease &nbsp;
                </td>
                <td>
                    <p>
                        If the following is met:
                    </p>
                    <p>
                        Severe symptoms plus any of the following
                    </p>
                    <ol>
                        <li data-list-item-id="e3fc9975b8ae38992cc64fc2dd7df88f2">
                            &nbsp; &nbsp;Hepatic decompensation
                        </li>
                        <li data-list-item-id="e7db8ed43550da79907032bdbce829ac6">
                            &nbsp; &nbsp;Concurrent hemodialysis or GFR less than 20 ml/min&nbsp;
                        </li>
                    </ol>
                </td>
            </tr>
            <tr>
                <td>
                    Primary Sclerosing Cholangitis&nbsp;
                </td>
                <td>
                    <p>
                        If any of the following is met:
                    </p>
                    <ol>
                        <li data-list-item-id="ed79f3e038dbe68e3452b1481c188c9b2">
                            &nbsp; &nbsp;2 culture-proven bacteremia within a 6 month period or who have a septic complication of bacterial cholangitits including either a biliary or hepatic abscess, bacterial meningitis, bacterial endocarditis, bacterial osteomyelitis, fungaemia. Bacteremia should be non-iatrogenic ( unrelated to a procedure such as ERCP or PTC.
                        </li>
                        <li data-list-item-id="ecf0b8f19f81111c6e794db81b953984c">
                            &nbsp; &nbsp;Bacterial cholangitis episodes should occur in patients who have been treated with antibiotic therapy that failed to suppress these septic episodes.&nbsp;
                        </li>
                    </ol>
                </td>
            </tr>
            <tr>
                <td>
                    Small for Size Syndrome&nbsp;
                </td>
                <td>
                    <p>
                        If the following is met:
                    </p>
                    <ol>
                        <li data-list-item-id="e651f70697ff0216ae29e62f754d63f01">
                            &nbsp; &nbsp;Confirmed diagnosed &nbsp;small for size syndrome based on size discrepancy. &nbsp;
                        </li>
                        <li data-list-item-id="eff12db4e90c5a57b095b23afb1d3ae70">
                            &nbsp; &nbsp;Failed treat for small for size syndrome.
                        </li>
                        <li data-list-item-id="ea4749dccfaa73b69f81308c96e85c5c6">
                            &nbsp; &nbsp; prolonged stay in the hospital/ ICU.&nbsp;
                        </li>
                    </ol>
                </td>
            </tr>
            <tr>
                <td>
                    Diffuse Ischemic Cholangiopathy&nbsp;
                </td>
                <td>
                    <p>
                        If the following is met:
                    </p>
                    <ol>
                        <li data-list-item-id="e5d6830ba60c3e1c5d0660eb25a8329f7">
                            &nbsp; &nbsp;Persistent cholestasis ( bilirubin above 35).
                        </li>
                        <li data-list-item-id="e95432d9e58a495a126d3c5a7cd996b79">
                            &nbsp; &nbsp;≥ 2 cholangitis with an associated bacteremia requiring admission. &nbsp;
                        </li>
                        <li data-list-item-id="ef82e6a06bce01edaf3236fef3500afdd">
                            &nbsp; &nbsp;Non-anastomotic biliary strictures not responsive to treatment.&nbsp;
                        </li>
                    </ol>
                </td>
            </tr>
            <tr>
                <td>
                    Late hepatic artery thrombosis &nbsp;
                </td>
                <td>
                    <p>
                        If the following is met:
                    </p>
                    <ol>
                        <li data-list-item-id="ea00606553e77eb8373eab31c91921573">
                            &nbsp; &nbsp;≥ 2 cholangitis with an associated bacteremia requiring admission.
                        </li>
                    </ol>
                    <p>
                        &nbsp; &nbsp;Non-anastomotic biliary strictures not responsive to treatment
                    </p>
                    <p>
                        &nbsp;
                    </p>
                </td>
            </tr>
            <tr>
                <td>
                    Combined Transplants&nbsp;
                </td>
                <td>
                    <p>
                        From the same Donor
                    </p>
                    <ol>
                        <li data-list-item-id="ea19d7ee45d7a266ddca2970cdac335cb">
                            &nbsp; &nbsp;Liver- intestinal transplant
                        </li>
                        <li data-list-item-id="e7c9ec23fe13d31b27a5c1beeb254a258">
                            &nbsp; &nbsp;Liver-kidney transplant OR Liver pancreas transplant:
                            <ol>
                                <li data-list-item-id="e10ab94d6b95cc58e30e53e57355fb0a0">
                                    &nbsp; &nbsp;CKD and EGF less than 30
                                </li>
                                <li data-list-item-id="eb5b3ae1ee32140307672a411caa0ff71">
                                    &nbsp; &nbsp;AKI needing HD for more than 12 weeks &nbsp;
                                </li>
                                <li data-list-item-id="eb9630d570cfdd6057c9d0ab371a607c4">
                                    &nbsp; &nbsp;&gt;30% fibrosis and glomerulosclerosis on renal biopsy
                                </li>
                            </ol>
                        </li>
                        <li data-list-item-id="ee953c7674ebc97a3c79b6e0a4c55f759">
                            &nbsp; &nbsp;Liver-Heart or Liver-Lung Transplant
                            <ol>
                                <li class="ck-list-marker-bold" data-list-item-id="e5529bcf3f1ee4f73733bc85d0e75f1f8">
                                    <strong>&nbsp; &nbsp;Assigned 42 Points&nbsp;</strong>
                                </li>
                            </ol>
                        </li>
                    </ol>
                </td>
            </tr>
            <tr>
                <td>
                    Cholangiocarcinoma&nbsp;
                </td>
                <td>
                    <p>
                        Within Mayo protocol
                    </p>
                    <p>
                        &nbsp;
                    </p>
                    <p>
                        Indicated in patients with hilar cholangiocarcinoma with: &nbsp;
                    </p>
                    <ol>
                        <li data-list-item-id="ece9d33ca25a61ed7deedd22842058b8b">
                            Unresectable Cholangiocarcinoma &nbsp;
                        </li>
                        <li data-list-item-id="e558f382246be53543ab8c2fe6625dc7c">
                            Diagnosis of Cholangiocarcinoma is established by CT/MRI/MRCP demonstrating a malignant looking mass less than 3 cm or a dominant stricture at the extrahepatic hilar bile duct (above the cystic duct) AND confirmed diagnosis with intraluminal brush cytology or intraluminal biopsy or biliary aneuploidy on FISH (in the absence of histological confirmation, a CA19-9 greater than 100 as an alternative).
                        </li>
                    </ol>
                    <p>
                        <strong>Exclusion criteria: &nbsp;</strong>
                    </p>
                    <ol>
                        <li data-list-item-id="e357f01610db3ff32f391876d5af09ea9">
                            Pre-treatment imaging showing suspicious disease outside the hilar bile duct
                        </li>
                        <li data-list-item-id="e3ac4ada4d7bc029333259df7f347030f">
                            Previous chemotherapy or radiation therapy, uncontrolled infection, prior attempt at biliary resection, &nbsp;
                        </li>
                        <li data-list-item-id="eec5b5259af2259ad8786a7ecd5f2ce8c">
                            Previous malignancy other than skin or cervical cancer in the last 5 years
                        </li>
                        <li data-list-item-id="ebde882039cd42d4092a4d68d824e68ea">
                            Contraindication to liver transplant
                        </li>
                        <li data-list-item-id="e24ff0cd2231dd5a8b12ab13dbc1d574f">
                            Hilar tumors extended below the cystic duct, vascular encasement, Unilateral ductal dilation with contra lateral vascular encasement, Unilateral atrophy with either contralateral ductal or vascular involvement. &nbsp;
                        </li>
                        <li data-list-item-id="e414c3650041e43f7eb68079ef94814a2">
                            Post-chemoradiation imaging or surgery staging demonstrating nodal disease, metastases, peritoneal metastases or extend to below the cystic duct.&nbsp;
                        </li>
                    </ol>
                </td>
            </tr>
            <tr>
                <td>
                    Cystic Fibrosis&nbsp;
                </td>
                <td>
                    Signs of Portal Hypertension&nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    Failed living donor or DCD&nbsp;
                </td>
                <td>
                    Transplanted within acceptable criteria and graft failure is due to biliary or vascular complication&nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    Familiar amyloid polyneuropathy &nbsp;
                </td>
                <td>
                    Significant symptoms and not responding to medical therapy&nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    Hepatoblastoma &nbsp;
                </td>
                <td>
                    Diagnosis&nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    Primary hyperoxaluria &nbsp;
                </td>
                <td>
                    Diagnosis&nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    HCC &nbsp;
                </td>
                <td>
                    <p>
                        Criteria:
                    </p>
                    <ol>
                        <li data-list-item-id="e0eddd0c3724e5fce6496d986f0e10f99">
                            One HCC nodule ≥ 2cm &nbsp;
                        </li>
                        <li data-list-item-id="e6b0502fcf96d02ce0cba95b52880b71a">
                            Multiple HCC nodules ≥ 1cm &nbsp;
                        </li>
                        <li data-list-item-id="ea04314df8ec71b7d904f1706487be696">
                            One HCC nodule 1-2cm that cannot be treated by intent to cure &nbsp;
                        </li>
                        <li data-list-item-id="e176d37650800bd116aa9fb3efac25e3c">
                            Recurrent HCC nodule ≥ 1cm. &nbsp;
                        </li>
                    </ol>
                    <p>
                        HCC must also fulfill all the following criteria (no contraindications) &nbsp;
                    </p>
                    <ol>
                        <li data-list-item-id="e40c742618c0a2037cc79fe981767f083">
                            &nbsp; &nbsp;Total Tumor Volume (TTV) ≤ 145cm3 &nbsp;
                        </li>
                        <li data-list-item-id="e6fd99f32fa708d3baabc50c59d52d055">
                            &nbsp; &nbsp;Alpha Fetoprotein (AFP) ≤ 1,000
                        </li>
                        <li data-list-item-id="ebb2da494be49c7bed68e36a4a2b3fbe0">
                            &nbsp; &nbsp;No evidence of vascular invasion or extrahepatic spread &nbsp;
                        </li>
                        <li data-list-item-id="e34b2863ba32d37ce096beda6f76455e1">
                            &nbsp; &nbsp;No HCC mixed with predominance of cholangiocarcinoma features on histology. &nbsp;
                        </li>
                    </ol>
                    <p>
                        &nbsp;
                    </p>
                    <p>
                        HCC patients not fulfilling the specified criteria (outlined above) do not receive exception points but can be actively listed.&nbsp;
                    </p>
                </td>
            </tr>
        </tbody>
    </table>

<p>
    The following conditions have no exception points:
</p>
<ul>
    <li data-list-item-id="e92ae4568208666c04a095d98b027977e">
        &nbsp; &nbsp;Ascites
    </li>
    <li data-list-item-id="eaa3fcb4e5da0a209180da06da1555a57">
        &nbsp; &nbsp;GI Bleeding
    </li>
    <li data-list-item-id="eed0216cd982e608df02b614615146748">
        &nbsp; &nbsp;Hepatic Encephalopathy
    </li>
    <li data-list-item-id="eb6ddc251f3aed23947bef430bfb1960a">
        &nbsp; &nbsp;Chronic Rejection
    </li>
</ul>
<p>
    &nbsp;
</p>
<p>
    Other exception points can be granted depending on discussion with the exception point committee.
</p>